Fulcrum Therapeutics (FULC) Free Cash Flow: 2019-2025
Historic Free Cash Flow for Fulcrum Therapeutics (FULC) over the last 7 years, with Sep 2025 value amounting to -$14.3 million.
- Fulcrum Therapeutics' Free Cash Flow rose 25.70% to -$14.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$60.3 million, marking a year-over-year decrease of 579.50%. This contributed to the annual value of -$2.5 million for FY2024, which is 97.27% up from last year.
- Per Fulcrum Therapeutics' latest filing, its Free Cash Flow stood at -$14.3 million for Q3 2025, which was down 2.87% from -$13.9 million recorded in Q2 2025.
- In the past 5 years, Fulcrum Therapeutics' Free Cash Flow registered a high of $58.9 million during Q2 2024, and its lowest value of -$28.2 million during Q3 2022.
- For the 3-year period, Fulcrum Therapeutics' Free Cash Flow averaged around -$12.5 million, with its median value being -$19.2 million (2024).
- In the last 5 years, Fulcrum Therapeutics' Free Cash Flow plummeted by 399.02% in 2021 and then skyrocketed by 380.74% in 2024.
- Over the past 5 years, Fulcrum Therapeutics' Free Cash Flow (Quarterly) stood at -$22.4 million in 2021, then increased by 11.46% to -$19.8 million in 2022, then fell by 17.28% to -$23.2 million in 2023, then climbed by 27.44% to -$16.9 million in 2024, then increased by 25.70% to -$14.3 million in 2025.
- Its Free Cash Flow was -$14.3 million in Q3 2025, compared to -$13.9 million in Q2 2025 and -$15.3 million in Q1 2025.